MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,166,209
Free Cash flow
-$15,114,705
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from the issuance of sh...
Proceeds from short-term investm...
Share-based compensation
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Net loss for the period
Increase (decrease) in amounts r...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-04-30
2025-10-31
2025-07-31
Net loss for the period
-14,533,948
-8,278,328
-26,556,140
Amortization
7,635
3,818
15,271
Financial income, net
143,204
-
-
Depreciation
52,032
22,839
91,356
Share-based compensation
718,063
294,686
776,879
Share of loss on equity investment
-126,296
-44,830
-224,212
Change in fair value of the warrant liability
-335,019
69,201
-758,364
Decrease (increase) in amounts receivable
-
-
-733,629
Unrealized gain on investment
48,343
89,487
56,473
Decrease in prepaid expenses
-
-
-492,279
Increase (decrease) in amounts receivable and prepaid expenses
-1,103,891
887,860
-
Decrease in accounts payable
45,522
-1,154,788
-3,887,078
Increase in accrued expenses and other payables
227,201
494,573
753,909
Total cash flow from operating activities
-14,987,656
-7,704,796
-28,170,520
Purchase of equipment
127,049
-
-
Purchase of short-term investments
15,781,000
-
7,316,000
Proceeds from short-term investments
7,372,473
-
-
Equity investment in bc therapeutics
185,000
75,000
330,000
Total cash flow from investing activities
-8,720,576
-75,000
-7,646,000
Proceeds from exercise of warrants
-
-
821,015
Proceeds from the issuance of shares, net of issuance costs
27,874,441
-
44,627,224
Total cash flow from financing activities
27,874,441
-
45,448,239
Increase (decrease) in cash and cash equivalents
4,166,209
-7,779,796
9,631,719
Cash and cash equivalents at beginning of the period
2,714,012
10,493,808
862,089
Cash and cash equivalents at end of the period
6,880,221
2,714,012
10,493,808
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of shares, net of...
$27,874,441
Total cash flow from
financing activities
$27,874,441
Increase (decrease) in
cash and cash...
$4,166,209
Canceled cashflow
$23,708,232
Share-based compensation
$718,063
Increase in accrued
expenses and other...
$227,201
Share of loss on equity
investment
-$126,296
Depreciation
$52,032
Decrease in accounts
payable
$45,522
Amortization
$7,635
Proceeds from short-term
investments
$7,372,473
Total cash flow from
operating activities
-$14,987,656
Total cash flow from
investing activities
-$8,720,576
Canceled cashflow
$1,176,749
Canceled cashflow
$7,372,473
Net loss for the
period
-$14,533,948
Increase (decrease) in
amounts receivable and...
-$1,103,891
Purchase of short-term
investments
$15,781,000
Change in fair value of
the warrant...
-$335,019
Financial income, net
$143,204
Unrealized gain on
investment
$48,343
Equity investment in bc
therapeutics
$185,000
Purchase of equipment
$127,049
Buy us a coffee
BriaCell Therapeutics Corp. (BCTXZ)
BriaCell Therapeutics Corp. (BCTXZ)